Pratik S. Multani

6.0k total citations · 1 hit paper
64 papers, 2.8k citations indexed

About

Pratik S. Multani is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Pratik S. Multani has authored 64 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Oncology, 29 papers in Pulmonary and Respiratory Medicine and 19 papers in Pathology and Forensic Medicine. Recurrent topics in Pratik S. Multani's work include Lung Cancer Treatments and Mutations (25 papers), Lymphoma Diagnosis and Treatment (17 papers) and Radiopharmaceutical Chemistry and Applications (8 papers). Pratik S. Multani is often cited by papers focused on Lung Cancer Treatments and Mutations (25 papers), Lymphoma Diagnosis and Treatment (17 papers) and Radiopharmaceutical Chemistry and Applications (8 papers). Pratik S. Multani collaborates with scholars based in United States, South Korea and Japan. Pratik S. Multani's co-authors include Leo I. Gordon, Gregory A. Wiseman, Thomas E. Witzig, Christos Emmanouilides, Myron S. Czuczman, Christine A. White, Nancy L. Bartlett, Antonio J Grillo-López, Brad Pohlman and Christine A. White and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Pratik S. Multani

61 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma

2002 841 citations Leo I. Gordon, Pratik S. Multani et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Pratik S. Multani United States	19	1.4k	1.2k	1.2k	811	424	64	2.8k
Lapo Alinari United States	30	1.7k 1.2×	487 0.4×	793 0.7×	419 0.5×	491 1.2×	115	2.8k
Bryan R. Leigh United States	26	561 0.4×	798 0.7×	762 0.7×	784 1.0×	267 0.6×	49	2.1k
Achiel Van Hoof Belgium	18	1.9k 1.4×	300 0.2×	1.3k 1.2×	388 0.5×	918 2.2×	33	2.6k
Manfred Welslau Germany	19	1.4k 1.0×	1.6k 1.3×	4.1k 3.6×	1.5k 1.8×	1.2k 2.7×	79	5.4k
Isabelle Bence‐Bruckler Canada	18	2.0k 1.4×	995 0.8×	1.5k 1.3×	216 0.3×	1.4k 3.2×	62	3.5k
Joke W. Baars Netherlands	23	899 0.6×	301 0.3×	935 0.8×	276 0.3×	507 1.2×	52	2.4k
Andreas Lohri Switzerland	24	2.1k 1.4×	314 0.3×	1.5k 1.3×	521 0.6×	735 1.7×	69	2.8k
Enrico Derenzini Italy	25	1.2k 0.8×	248 0.2×	766 0.7×	275 0.3×	344 0.8×	99	1.9k
Alex F. Herrera United States	28	2.1k 1.5×	366 0.3×	2.5k 2.2×	218 0.3×	587 1.4×	239	3.5k
Wojciech Jurczak Poland	22	2.3k 1.6×	345 0.3×	1.5k 1.3×	289 0.4×	1.6k 3.7×	281	3.4k

Countries citing papers authored by Pratik S. Multani

Since Specialization

Citations

This map shows the geographic impact of Pratik S. Multani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pratik S. Multani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pratik S. Multani more than expected).

Fields of papers citing papers by Pratik S. Multani

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pratik S. Multani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pratik S. Multani. The network helps show where Pratik S. Multani may publish in the future.

Co-authorship network of co-authors of Pratik S. Multani

This figure shows the co-authorship network connecting the top 25 collaborators of Pratik S. Multani. A scholar is included among the top collaborators of Pratik S. Multani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pratik S. Multani. Pratik S. Multani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Junttila, Melissa R., Claire E. Repellin, Jason E. Long, et al.. (2024). 62 (PB050): ORIC-114, a highly selective, brain penetrant EGFR and HER2 inhibitor, demonstrates best-in-class properties against Exon 20 insertions and other atypical EGFR mutations. European Journal of Cancer. 211. 114589–114589. 2 indexed citations

Hong, Min Hee, Alexander I. Spira, Ki Hyeong Lee, et al.. (2023). 1333P A global phase 1b study of ORIC-114, a highly selective, brain penetrant EGFR and HER2 inhibitor, in patients with advanced solid tumors harboring EGFR Exon 20 or HER2 alterations. Annals of Oncology. 34. S769–S769. 5 indexed citations

Demetri, George D., Luis Paz‐Ares, Anna F. Farago, et al.. (2018). Efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001. Annals of Oncology. 29. ix175–ix175. 30 indexed citations

Demetri, George D., Luis Paz‐Ares, Anna F. Farago, et al.. (2018). Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) Tumors: Pooled analysis of STARTRK-2, STARTRK-1 and ALKA-372-001. Annals of Oncology. 29. viii713–viii713. 46 indexed citations

Doebele, Robert C., Myung‐Ju Ahn, Salvatore Siena, et al.. (2018). OA02.01 Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 13(10). S321–S322. 36 indexed citations

Drilon, Alexander, Stephen V. Liu, Robert C. Doebele, et al.. (2017). A phase 1b study of RXDX-105, a VEGFR-sparing potent RET inhibitor, in RETi-naïve patients with RET fusion-positive NSCLC. Annals of Oncology. 28. v612–v612. 9 indexed citations

Sigal, Darren, Marie Tartar, Patrick J. Foley, et al.. (2017). Activity of Entrectinib in a Patient With the First Reported NTRK Fusion in Neuroendocrine Cancer. Journal of the National Comprehensive Cancer Network. 15(11). 1317–1322. 32 indexed citations

Somwar, Romel, James D. Joseph, Roger S. Smith, et al.. (2016). Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations. Clinical Cancer Research. 23(12). 2981–2990. 49 indexed citations

Farago, Anna F., Long P. Le, Zongli Zheng, et al.. (2015). Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 10(12). 1670–1674. 172 indexed citations

10.

Cutler, Corey, Caroline Desponts, David Robbins, et al.. (2011). Ex Vivo Treatment of Hematopoietic Stem Cells With 16,16-Dimethyl Prostaglandin E2 (FT1050) Improves Engraftment and Hematopoietic Reconstitution. Biology of Blood and Marrow Transplantation. 17(2). S226–S226. 2 indexed citations

11.

Marcelletti, John F., Pratik S. Multani, Jeffrey E. Lancet, Maria R. Baer, & Branimir I. Šikić. (2008). Leukemic blast and natural killer cell P-glycoprotein function and inhibition in a clinical trial of zosuquidar infusion in acute myeloid leukemia. Leukemia Research. 33(6). 769–774. 11 indexed citations

12.

Theuer, Charles P., Bryan R. Leigh, Pratik S. Multani, R. S. Allen, & Bertrand C. Liang. (2004). Radioimmunotherapy of non-Hodgkin’s lymphoma: Clinical development of the Zevalin regimen. PubMed. 10. 265–295. 15 indexed citations

13.

Multani, Pratik S.. (2002). Report of the Fifteenth International Symposium of the Foundation for Promotion of Cancer Research: New Horizons in the Diagnosis and Treatment of Hematological Malignancies Based on Molecular Genetic Features. Japanese Journal of Clinical Oncology. 32(9). 371–385. 2 indexed citations

14.

Nabhan, Chadi, Lo Ann C. Peterson, Martin S. Tallman, et al.. (2002). Secondary Acute Myelogenous Leukemia with MLL Gene Rearrangement Following Radioimmunotherapy (RAIT) for Non-Hodgkin's Lymphoma. Leukemia & lymphoma. 43(11). 2145–2149. 6 indexed citations

15.

Multani, Pratik S.. (2002). Development of Radioimmunotherapy for the Treatment of Non-Hodgkin’s Lymphoma. International Journal of Hematology. 76(5). 401–410. 8 indexed citations

16.

Multani, Pratik S., et al.. (2001). Non-Hodgkins Lymphoma: Review of Conventional Treatments. Current Pharmaceutical Biotechnology. 2(4). 279–291. 22 indexed citations

17.

Grillo-López, A.J., B.K. Dallaire, A McClure, et al.. (2001). Monoclonal Antibodies: A New Era in the Treatment of Non-Hodgkins Lymphoma. Current Pharmaceutical Biotechnology. 2(4). 301–311. 17 indexed citations

18.

Spitzer, Thomas R., Steven L. McAfee, Robert Sackstein, et al.. (2000). Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies. Biology of Blood and Marrow Transplantation. 6(3). 309–320. 204 indexed citations

19.

McAfee, SL, Robert Sackstein, Pratik S. Multani, et al.. (2000). High-dose cyclophosphamide + carboplatin and interleukin-2 (IL-2) activated autologous stem cell transplantation followed by maintenance IL-2 therapy in metastatic breast carcinoma – a phase II study. Bone Marrow Transplantation. 25(1). 19–24. 12 indexed citations

20.

Chabner, Bruce A., Anthony Boral, & Pratik S. Multani. (1998). Translational research: walking the bridge between idea and cure--seventeenth Bruce F. Cain Memorial Award lecture.. PubMed. 58(19). 4211–6. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact